Acceleron raises $30m to advance orphan and oncology portfolio
This article was originally published in Scrip
Executive Summary
Acceleron Pharma, which develops protein therapeutics for cancer and orphan diseases, has raised a $30 million private financing bolstering an already enviable financial position. All of Acceleron's existing investors, including its partner Celgene, participated in the round.